ViGenCell

바이젠셀 · 308080

Industrials Commercial Services · KOSDAQ

Small-cap

Market cap US$148.5M (₩205B)

Overview

ViGenCell develops cell-based therapies, treatments that use a patient's own or donor immune cells to fight disease, aimed at medical institutions and patients in need of advanced therapeutic options.

The company is listed on KOSDAQ, South Korea's technology and small-cap stock exchange, under a special listing track reserved for technology-growth companies that have not yet reached profitability. Its Australian subsidiary was dissolved during the most recent reporting period, leaving it focused on its domestic operations.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$16.4K

▼ −91.9% YoY

Operating profit · FY2025

−US$12.4M

Loss widened

Net income · FY2025

−US$11.8M

Loss widened

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$0(₩0)	US$202.1K(₩278.9M)	US$16.4K(₩22.7M)
Operating profit	−US$14.6M(−₩20.1B)	−US$11.1M(−₩15.3B)	−US$12.4M(−₩17.1B)
Net income	−US$13M(−₩17.9B)	−US$10.2M(−₩14.1B)	−US$11.8M(−₩16.3B)

Revenue

FY2023US$0
FY2024US$202.1K
FY2025US$16.4K

Operating profit

FY2023−US$14.6M
FY2024−US$11.1M
FY2025−US$12.4M

Net income

FY2023−US$13M
FY2024−US$10.2M
FY2025−US$11.8M

Key ratios (FY2025)

ROE

-846.0%

Debt/Eq

547.1%

Op. margin

-75453.1%

Net margin

-71986.4%

Rev. YoY

▼ −91.9%

Why it matters

ViGenCell was admitted to KOSDAQ under a technology-growth special listing exemption, a track that allows pre-profit biotech firms to list based on technological merit rather than financial results.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?